Withanolide B
Names
Biological Activity
[Description]:
Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].
[Related Catalog]:
[In Vitro]
Withanolide B (1-100 nM; 3-5 days) significantly increases the expression of COL1A1 and RUNX2 genes and proteins in hBMSCs[1]. Withanolide B (1-100 nM; 11 or 3 days) increases the formation of extracellular matrix calcium deposits and increased the activity of alkaline phosphatase (ALP)[1]. Withanolide B (1-100 nM; 3-5 days) increases the protein expressions of p-ERK and active β-catenin of hBMSCs[1]. Withanolide B (10-100 μM; 48 h) reverses the Aβ42 aggregation-induced toxicy in SK-N-SH cells[2]. Cell Viability Assay[1] Cell Line: Human bone mesenchymal stem cells Concentration: 1, 10, 100 nM Incubation Time: 3, 5 days Result: Significantly increased the expression of COL1A1 and RUNX2.
[In Vivo]
Withanolide B (10 mg/kg; topical administration) promotes bone healing in a rat tibial defect model[1]. Animal Model: Male Sprague-Dawley rats (8 weeks, 200 g) with tibial defect[1] Dosage: 10 mg/kg Administration: Injected in situ at the bone defect site at different time points (0, 3, 5, 7, and 9 days) Result: Increased the trabecular number, trabecular thickness and the thickness of the cortical bone.
[References]
Chemical & Physical Properties
[ Density]:
1.206
[ Molecular Formula ]:
C28H38O5
[ Molecular Weight ]:
454.59800
[ Exact Mass ]:
454.27200
[ PSA ]:
76.13000
[ LogP ]:
4.38050
Safety Information
[ Hazard Statements ]:
H413
[ RIDADR ]:
NONH for all modes of transport